ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Income Statement
NASDAQ:RARE - Nasdaq - US90400D1081 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 590.69M | 560.23M | 434.25M | 363.30M | 351.40M | |||
| Cost Of Goods | 87.86M | 76.73M | 45.21M | 28.30M | 16.00M | |||
| Gross Profit | 502.83M | 483.50M | 389.04M | 335.00M | 335.40M | |||
| Operating Expenses | 1.02B | 1.02B | 958.25M | 983.90M | 717.10M | |||
| Research and Development | 685.15M | 692.37M | 644.65M | 702.60M | 496.90M | |||
| Selling, General, and Administrative Expenses | 331.25M | 321.61M | 309.80M | 278.10M | 220.00M | |||
| Operating Income | -513.57M | -535.97M | -569.21M | -648.90M | -381.70M | |||
| Interest Income/Expense | 22.66M | 35.39M | 27.09M | -8.20M | -40.10M | |||
| Other Income/Expense | -56.23M | -67.00M | -66.34M | -44.60M | -31.10M | |||
| Income Before Taxes | -547.13M | -567.59M | -608.46M | -701.70M | -453.00M | |||
| Income Tax | 2.45M | 1.60M | -1.82M | 5.70M | 1.00M | |||
| Net Income | -549.58M | -569.18M | -606.64M | -707.40M | -454.00M | |||
| EBITDA | N/A | -500.43M | -543.20M | -630.68M | -368.46M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -5.88 | -6.29 | -8.25 | -10.12 | -6.70 | |||
| Non GAAP EPS | -5.88 | -6.34 | -8.33 | -10.11 | -6.71 | |||
| Statistics | ||||||||
| Gross Profit Margin | 85.13% | 86.30% | 89.59% | 92.21% | 95.45% | |||
| Profit Margin | -93.04% | -101.60% | -139.70% | -194.72% | -129.20% | |||
| Operating Profit Margin | -86.94% | -95.67% | -131.08% | -178.61% | -108.62% | |||
All data in USD